Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.

Biological markers such as disease risk and mutation profile can predict survival outcomes of acute myeloid leukemia (AML) treated with first-line venetoclax (Ven) in combination with a hypomethylating agent. However, the impact of socioeconomic factors with this regimen is unclear. Using a widely validated metric of disadvantage, Area Deprivation Index (ADI), we investigated the influence of socioeconomic disparity on overall survival (OS) in seventy-nine newly diagnosed patients with AML who received Ven-based therapy at the University of Wisconsin. Median OS was 6.77 months (IQR 2.52-11.57) with a cumulative mortality rate of 75.9%. While previous reports demonstrated worse outcomes in disadvantaged patients treated with intensive therapy, we observed no statistically significant difference between State/National ADI and OS (p = 0.697 and p = 0.582 respectively) in our Ven cohort.